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PREFACE
The main body of this thesis in Chapter III is a journal article titled “Inhibition and Eradication
of Bacterial Biofilm by Injectable Mannitol-Chitosan Paste” This manuscript is to be submitted
to MDPI Marine Drugs Journal.

v

ABSTRACT
Implanted materials can increase the risk of osteomyelitis, leading S. aureus to develop a
biofilm not only on the materials, but also in bone and soft tissue surrounding the joint. Biofilm
is intrinsically less susceptible to antibiotic therapy than free-floating planktonic microorganisms
due to decreased metabolic rates of persister cells. Mannitol has been shown to activate persister
cell metabolism, priming microorganisms for the uptake of antibiotics and subsequent
eradication. Blends of mannitol and chitosan were evaluated in elution and activity studies to
determine the efficacy against biofilm with additional injectability, degradation, and biofilm
eradication evaluations. Results indicate the mannitol/chitosan blend is capable of eluting
antibiotics for up to 7 days and antimicrobial activity up to 7 days. Clinically, this paste could
serve as a biodegradable local antibiotic delivery system at the time of surgery to prevent
infection, during periprosthetic joint surgeries, or complex musculoskeletal trauma to prevent
and treat infection.
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CHAPTER I
INTRODUCTION
Statement of Clinical Problem
Total joint arthroplasties (TJA) are surgeries than can be an effective means to improve
the quality of life and restore function in patients faced with rheumatoid arthritis, osteoarthritis,
or articular damage [1, 2]. Over 1 million TJA are performed each year in the United States, and
are predicted to increase dramatically in the next decade[3, 4]. Recent estimates project that total
hip arthroplasties (THA) performed in the UK and USA will exceed 570,000 procedures per year
and total knee arthroplasties (TKA) will exceed 3.45 million procedures per year by 2030 [5, 6].
In the terms of estimated cost, it is projected that Medicare’s spending on TJA will increase up to
$50 billion annually [7]. Periprosthetic joint infections (PJI) are a common mode of failure in
TJA and occur in up to 1% in THA and up to 2% in TKA [8, 9]. Despite this seemingly low
percentage, PJI serves as the leading cause for revision in failed TKA (25.2% of all knee
revisions) and the third leading cause for THA (14.8% of all hip revisions) [10-12]. The
economic burden of treating a PJI is associated with extremely high, with costs up to $100,000
per treatment due to longer hospital stays, higher complication rates, lengthened rehabilitation
time, and the extended use of antibiotics and analgesics [8, 10, 13, 14]. Combining the estimated
increase in number of TJA performed annually and the occurrence of PJI, healthcare costs could
exceed $7 billion [14].
The biomaterials used in orthopedic implants can serve as initial bacterial attatment sites
and subsequently the formation of a biofilm, a complex community of bacteria with intrinsic
antibiotic resistance [15]. Microorganisms can colonize the surface of typical orthopedic
materials, such as colbat-chromium, titanium, and polyethylene, and form a biofilm after being
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introduced directly into the joint cavity during surgery or from a hemotogenous infection. [16,
17]. During this process, bacterial cells secrete an extracellular polymeric substance (EPS)
matrix consisting of proteins, polysaccharides, lipids, and nucleic acids [18-21]. This matrix
serves as an anchor for the developing biofilm, is used as a defense mechanism against the host’s
immune system and decreases the diffusion rate of antibiotics [18-21]. Within biofilm, bacteria
tend to enter a lower metabolic state characterized by persister cells, a phenotypic state of the
bacteria which is capable of withstanding up to 1000x the therapeutic concentration of antibiotics
[22]. The clinical need for the implementation of a system to achieve complete microbe
elimination from an infection site during a prosthetic joint revision surgery is critical [23].
Among methods to target elimination of biofilm are strategies to activate and eradicate persister
cells within the biofilm [24-26].
While there are limited options for treatment of existing infection, preventative measures
include antibiotic prophylaxis to reduce the risk of infection and use of chlorhexidine-based,
povidone-iodine-based, or alcohol-based solutions to prepare the skin [27, 28]. Additionally,
some orthopedic surgeons choose to administer the antibiotic vancomycin directly to the joint
space by way of the “vancomycin sprinkle” [29]. The current standard method for treating PJI is
a two-stage revision surgery, with numerous studies showing eradication rates as high as 95%
[30, 31]. During two-stage revision surgeries, either a static or reticulating antibiotic spacer is
used as a local antibiotic delivery device after the infected prosthetic joint has been removed and
the surrounding infected tissue has been debrided; this spacer is later removed during the second
surgery and replaced by the new implant [31]. Other forms of treatment include one-stage
revisions and a technique known as debridement, antibiotics and implant retention (DAIR)
treatment [32, 33]. The method of treatment depends on the preference of the orthopedic
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surgeon, severity of infection, and patient risk-factors, such as diabetes, heart disease, and
obesity [11, 34]. Although one-stage revisions and the DAIR method have advantages like
reduced costs, shorter hospital stays, and implant retention, these methods have been shown to
have incidence rates of recurring infection as high as 17% and 44% respectively [35-38]. This
high recurrence rate could be attributed to the fact that a local antibiotic delivery system is not
employed during these surgeries, leading to only partial eradication of the microorganism(s)
causing the infection.
Injectable and biodegradable antimicrobial delivery systems may improve outcomes for
one-stage revisions or the DAIR technique by releasing antibiotics at high concentrations to
inhibit and eradicate biofilm [39]. Recent studies have examined the drug delivery capabilities
of chitosan, a naturally abundant biopolymer derived from the exoskeletons of crustaceans,
which has been used in a variety of therapeutic delivery systems [40, 41]. Chitosan is
characterized by its biocompatibility, biodegradability, mucoadhesivity, and intrinsic
antimicrobial properties [42]. Chitosan has been developed in to a number of systems including
sponges used for bacterial prevention [43-45]. Additionally, groups have developed chitosan
pastes, with the addition of polyethylene glycol (PEG), as an injectable delivery system for the
treatment of infections in the context of complex musculoskeletal trauma [46, 47]. Others have
developed a thermosensitive gel from chitosan and beta-gylcerophoshate, highlighting its elution
and antimicrobial activity [48]. These pastes offer the advantage of conformability to complex
wound beds, but do not include biofilm-targeting components against infection.
Mannitol, a sugar alcohol naturally found in marine algae and a known metabolite of
bacteria, has been shown to reverse the persister cell state and aid aminoglycosides in their
eradication of these bacteria [25, 26, 49]. Mannitol effectively acts to shift the direction of
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metabolic reactions within the persister cell to activate the cell’s metabolism, priming the
dormant bacterial cell for the uptake of antibiotics [25].
Hypothesis and Research Objectives
In this research chitosan paste with PEG was blended with 2% (weight/volume) mannitol
to form a local delivery biomaterial complex with improved targeting of persister cells for
increased eradication. It was hypothesized that the addition of mannitol would increase the
antimicrobial activity of the antibiotics loaded into the chitosan paste, while biocompatibility
would not be affected. Characterization studies of this novel biomaterial blend were performed to
outline the following properties: elution profiles of antibiotics and mannitol, biocompatibility,
degradation, injectability, and antimicrobial and anti-biofilm properties in vitro and in vivo. All
studies were compared to non-mannitol containing controls.
Specific research objectives were the following:
1. Determine the elution profile of the mannitol-chitosan paste and the antimicrobial activity
against Staphylococcus aureus (UAMS-1).
2. Test the biocompatibility of the mannitol-chitosan paste in vitro against fibroblasts
according to ISO 10993 with fibroblasts and in vivo with a rat using biocompatibility
model.
3. Evaluate the antibiofilm properties of the new mannitol-chitosan paste in vitro using
representative gram-positive and gram-negative pathogens and in vivo with an
osteomyelitis rabbit model.
4. Determine the degradability of the mannitol-chitosan paste.
5. Quantify the injectability of the paste through a standard 1 mL syringe and an 18G
needle.
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CHAPTER II
LITERATURE REVIEW
Biofilm throughout the Body
It was not until 1980 that infection was recognized as a direct result of not only
planktonic bacteria, but also bacteria dwelling within a biofilm [50]. Biofilms can be found in
many types of chronic infections including those involving native tissue and indwelling devices
[17]. Some of the most common native tissue associated infections include chronic sinusitis,
endocarditis, and osteomyelitis [51] Common indwelling device infections include those
associated with urinary tract infections, prosthetic valve endocarditis, vascular graft infections,
ventriculoperitoneal shunt infections, and ventilator-associated pneumonias [17]. Figure 1 below
gives a complete overview of areas in the body that can be affected by biofilms.

Figure 1. Common locations where biofilm infections can occur. [51]
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A biofilm forms when bacteria adhere directly to tissue or to implanted foreign materials,
such as joint replacements. The complex structure of biofilm is formed when these anchored
bacteria surround themselves with an extracellular polymeric substance (EPS) matrix consisting
of protein, polysaccharides, lipids, and nucleic acids, and humic substances [19-21]. These
networks of microorganisms communicate with one another via cell-cell signaling that facilitates
the participation of bacteria in quorum sensing [18]. In a way, quorum sensing (QS) can be
compared to the human endocrine system as its use allows bacteria to assess the local cell
population density and regulate gene expression by releasing extracellular molecules to facilitate
synchronized changes within the biofilm. These transcriptional changes can occur with the
exchange of plasmids between bacteria, which can confer genes for virulence factors and
antibiotic resistance, and commence the formation and secretion of the EPS matrix that supports
the biofilm [52]. This matrix not only anchors bacteria to their chosen surface, but it also
provides a nearly impenetrable defense mechanism, limiting the diffusion of antibiotics and
protecting the bacteria fromthe host immune system [23]. An established biofilm is often able to
survive physicochemical aggression including UV light, heavy metals, acidity, changes in
hydration or salinity, and phagocytosis [53-57]. The formed EPS matrix barrier also limits the
flow of fluid within the biofilm, effectively reducing the amount of available nutrients. This
limitation of nutrients pushes the bacteria to enter a no-growth or diminished-growth state that
resists growth-dependent antimicrobial agents, effectively rendering many antibiotics useless for
eradicating biofilms. The bacteria that enter this no-growth or diminished-growth state are
known as persister cells [24].
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Persister cells and recalcitrance
Recalcitrance is a characteristic of established biofilms that is described as the capacity of
a biofilm to withstand treatment or rather the non-susceptibility of a biofilm to antimicrobials
[58, 59]. It can also be used to characterize the ability of a subset of biofilm bacteria, described
earlier as the persister cell, to survive in the presence of antibiotics, later repopulating the
biofilms as planktonic bacteria, when the antibiotics are removed from the immediate
environment. These cells were first given this attribute when fluoroquinolones, an antibiotic
family able to easily penetrate biofilms and kill non-dividing cells, failed to eradicate an
established biofilm [60]. The persister cell phenotype makes up less than 1% of the total
population of bacteria in a biofilm, does not multiply in the presence of antibiotics, has an
antibiotic tolerance not related to any genetic modification, and resumes growth patterns equal to
a non-persister cell [24]. The analogy of “insurance” has been used to describe persister cells as
mechanism for the microbial community of a biofilm to ensure its survival even under times of
great stress [61]. Additionally, the persister cell phenotype is not limited to one type of bacteria
because both gram-negative and gram-positive bacteria display this particular mechanism,
making persister cells a broad target for combatting biofilms of many bacterial species [24].
Biofilms in Orthopedics
It is estimated that up to 80% of bacterial infections are known to be caused by organisms
growing in biofilms. The premise that biofilms are the etiological agents of all device-related
infections and other chronic bacterial infections highlights the importance in the field of
orthopedics [19, 62]. Gristina and Costerton applied the idea of a biofilm to device-related
orthopaedic infections as early as 1984 [63]. Indwelling materials, such as periprosthetic joint
implants have an increased risk of developing a biofilm [51, 64-66]. This initial colonization can
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happen from direct seeding at the time of insertion, contamination from the implant itself, or
from a hematogenous infection allowing the bacteria to attach to the prosthesis and develop an
infection. [14]. It has been shown that bacteria concentrations needed to induce an infection is
reduced by more than 100,000 times in the presence of a foreign body [67]. Even in cases in
which the innate and adaptive immune systems of the host were intact, device-related orthopedic
infections rarely resolved spontaneously leading to recurring infections [18]. These recurring
infections are due to the recalcitrance of the biofilm, which results in either the removal of the
device or potentially death, if the infection spreads throughout the body causing septic shock.
Biofilm formation can be influenced by a number of systemic host factors such as, age, nutrition,
smoking diabetes, and other co-morbidities, which can limit the patient’s ability to clear
contaminating microorganisms through the immune system [68]. In the field of orthopedic
trauma, open fractures are particularly susceptible to biofilm formation based on a multitude of
local factors including: extent of contamination, size of the wound, degree of soft tissue damage,
periosteal stripping, bone vascularity, and blood supply [17]. Bacteria will inevitably enter the
wound site and further colonize on bone or tissues, forming a biofilm within a matter of hours
[17]. The development of such a biofilm can cause tissue destruction that outpaces the healing
process of the fracture.
Within the context of periprosthetic joint infections (PJI) after total joint arthroplasty,
these infections are very similar to those formed after an orthopedic trauma. Due to the
indwelling implant, a race to the surface can occur in which bone ingrowth competes with the
bacterial growth with a biofilm forming after attachment [17]. PJI only happens in a small
percentage of patients who chose to undergo a TJA, only occurring in 1% of total hip
arthroplasties (THA) and up to 2% in total knee arthroplasties (TKA). However, as the estimated
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number of THAs performed in the UK and USA will increase to over 4 million procedures each
year by 2030 amounting to a considerable amount of people at risk of developing a PJI [5].
Estimates show PJI as the most common cause for revision surgeries in TKA at 25.2% and the
third most common cause for revision surgeries in THA at 14.8% of all hip revisions [10, 12,
69]. Patients affected by this disease deal with higher complication rates, lengthened hospital
stays and rehabilitation time, extended use of antibiotics and analgesics, and soaring healthcare
costs [14].
Current Treatment Options for PJI
The Centers for Disease Control and Prevention recommends to use preoperative
antibiotic administration prior to most orthopedic procedures [70, 71]. Therefore, the first
preventative measure before a TJA includes antibiotic prophylaxis to reduce the risk of infection.
It is understood that impeccable aseptic technique is the best way to reduce the risk of infection,
combined with the use of chlorhexidine-base, povidone-iodine-based, or alcohol-based solutions
to prepare the skin[14, 27-29]. Additionally, some orthopedic surgeons choose to administer
powder antibiotics, typically vancomycin, directly to the joint space before closure [29]. This has
been colloquially named the “vancomycin sprinkle,” with recent review articles highlighting the
benefits and limitations of this practice, particularly the Center for Disease Control’s official
position against the use of topically applied antibiotics [29, 70, 72] There is a serious lack of
high-quality data, but this practice is seen across the many realms of orthopedic surgery, first
becoming popular in the context of spinal surgeries [73-75]. The convience of a localized
immediate dose of antibiotics is cost efficient, but the duration of treatment is short, there is a
possibility of local or systemic toxicity, and this practice could lead to the development of
antibiotics resistant strains [29, 70]. Finally, understanding the patient and the risk factors that
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indicate an elevated chance of developing a PJI, while taking the appropriate measures, can
significantly reduce probability of an infection occurring. Risk factors include an active
systemic or local infection, history of previous surgeries, immunosuppressive medications,
uncontrolled diabetes mellitus, morbid obesity, depression, smoking, alcohol consumption,
intravenous drug abuse, skin problems, and daily use of non-steroidal anti-inflammatory
medications [16, 68, 76].
When the preventative measures fail, the first step is diagnosing a PJI, which can prove to
be quite challenging because the exact definition remains quite complex and the tests given
evaluate measures of an infection, and not the actual presence of PJI [16]. The Musculoskeletal
Infection Society (MSIS) has defined PJI as a set of criteria, in which one of two major criteria
or three of five minor criteria must be met [16]. The two major criteria include the presence of a
sinus tract directly to or from the prosthesis and a pathogen isolated in culture from at least two
separate tissue or fluid samples obtained from the affected joint [16]. The five minor criteria
include the following; elevated serum erythrocyte sedimentation rate and serum C-reactive
protein concentration, elevated synovial leukocyte count or positive result on leukocyte esterase
test strip, elevated synovial neutrophil percentage, isolation of a microorganism in one culture of
periprosthetic tissue or fluid, and greater than five neutrophils per high-power field in five highpower fields observed from histologic analysis of periprosthetic tissue at 9400 times
magnification [16].
After diagnosis, the gold standard is to approach the infection with a two-stage revision
surgery. The first stage involves the removal of all components of the prosthetic joint, the bone
cement, and compromised soft tissues surrounding the joint with the subsequent placement of an
antibiotic impregnated spacer used in conjunction with choice systemic antibiotics [77]. The
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second stage involves the removal of the spacer and the implementation of a new periprosthetic
joint. This surgical approach can offer significant challenges to a surgeon, as removing a wellfixed prosthesis is daunting task creating many surgical risks [35]. While some studies have
reported that two-stage revision surgeries can result in infection eradication rates as high as 95%
one stage revision surgeries have recently been reported to have better functional outcomes and
are more cost effective than the two-stage technique, though there are limited data sets [77-80].
One-stage revision surgeries involve exchanging the prosthesis after the debridement of infected
tissues within the same procedure [30]. This greatly decreases the time a patient must spend with
reduced mobility, while also decreasing the medical costs for reducing the number of hospital
stays. In a meta-analaysis, Nagra et al concluded that no difference in reinfection rates was
detected between one- and two-stage exchange arthroplasties, but with improved patient
selection and surgical management, one-stage procedures may decrease medical costs, reduce the
length of hospital stays, and increase quality of life in select patient cohorts [36].
Finally, the third technique for the management of a PJI is the DAIR method;
debridement, antibiotics and implant retention. This surgical technique is typically reserved for
patients presenting with an acute infection and a well-fixed prosthesis [36]. However, outcomes
are highly variable with the percent of infection eradication ranging from 14% to 100%,
depending on patient co-morbidities such as smoking, obesity, diabetes, and compromised
immune systems [36, 81, 82]. Not unlike the one-stage revision, patient outcomes in terms of
satisfaction and decreased hospital stays, along with decreasing medical, costs are improved with
this technique, especially decreasing the cost by retaining the implant [35].
Additionally, techniques including pulse lavage and low-frequency sonication have been
shown to be ineffective at eradicating biofilm present on the prosthesis [17, 83]. Low-frequency
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sonication is also said to have potentially damaging effects on implants by increasing surface
roughness [83]. One-stage revision surgeries and the DAIR technique have clear advantages in
the eyes of a patient, but could benefit from the implementation of a local antibiotic delivery
device for any remaining biofilm within the joint. An injectable, biodegradable material capable
of being loaded with choice-antibiotics could serve as another level of protection after the
closure of the wound, similar to the method of using an antibiotic spacer in two-stage revision
surgeries.
Chitosan as a Local Therapeutic Device
Chitosan, a naturally occurring linear polysaccharide, has been shown to be effective as a
local drug delivery system in several forms including: sponges, pastes, thin films, nanoparticles,
and hydrogels [46-48, 84-86]. Chitosan could offer a way to incorporate a biodegradable
material directly into the wound before closure in one-stage revision surgeries or DAIR surgical
techniques. It is comprised of randomly distributed β-(1-4)-2-amino-2-D-glucosamine
(deacetylated) and β-(1-4)-2-acetamido-2-D-glucoseamine (acetylated) units. It is obtained from
chitin, whose main source is the exoskeleton of shellfish, after undergoing an alkaline
deacetylation procedure. Chitosan can be characterized as chitin whose degree of deacetylation
(DDA) is greater than 50% [87-89]. As the DDA increases, the crystallinity of chitosan
increases, which in turn decreases the degradation rate [89-91]. It is naturally degraded in the
body by either lysozymes or acid dissolution [92, 93]. Chitosan has also been characterized by its
bioadhesive properties along with its ability to store and release drugs over time by
electrostatically interacting with the drugs themselves or by encapsulating the drugs within a
matrix [40, 88, 92, 94-96]. Due to these properties, it is being investigated and currently used for
many medical applications [92, 94]. Some of the medical applications currently being
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investigated at the University of Memphis include the following: chitosan sponge delivery
systems [43-45], magnetic chitosan nanoparticles for targeted drug delivery [84], coatings for
musculoskeletal implant fixation hardware [86, 97], chitosan pastes thermally induced to gel at
body temperature, and varying applications of injectable chitosan paste [46-48]. The studies
involved demonstrating the efficacy of these injectable chitosan pastes to serve as a device for
localized antibiotic delivery in order to reduce the rate of musculoskeletal wound infections.
Additionally, it has been demonstrated that chitosan has antimicrobial activity against many
different organisms due to its cationic nature [98]. Chitosan has been shown to display
antimicrobial properties against Escherichia coli, Pseudomonas Aeruginosa, Staphylococcus
epidermidis, and S. aureus [98]. Sudarshan et al demonstrated low-molecular-weight chitosan
can penetrate bacterial cell walls, bind with DNA, and inhibit DNA transcription and mRNA
synthesis [99]. High molecular weight chitosan was shown by Muzzarelli et al and Zheng et al
to bind to the negatively charged components on the bacterial cell wall, forming an impermeable
layer around the cell, changing cell permeability and blocking transport into the bacterial cell
[100, 101]. The exact mechanism of chitosan’s antimicrobial properties is still being researched
and debated.
Systems Targeting Biofilm
In recent years, a number of advanced therapeutic strategies have been studied that
specifically target biofilm in an effort to reduce infection, treatment times, and cost. Cis-2decenoic acid (C2DA), a member of the medium chain fatty acids acting as a diffusible signaling
factor in bacteria, is another molecule that has been well studied for its ability to inhibit biofilm
formation and disperse established biofilms of multiple strains [102]. Jennings et al showed the
mechanism of action may be due to the molecules ability to increase membrane permeability
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allowing for the penetration of more antibiotics [103]. However, the solubility of this fatty acid
makes it difficult to deliver. Harris et al recently performed a pilot studying examining C2DA
loaded into manually applied phosphatidylcholine coatings in a murine osteomyelitis model, in
which this system was able to inhibit S. aureus formation on Titanium pins and the bone, both
with and without antibiotics [104]. Another antimicrobial molecule of interest is lysostaphin, a
commercially available proteolytic enzyme produced by Staphylococcus simulans. This molecule
is shown to have antimicrobial properties specific to other Staphylococcus species [105]. It
works by attaching to the cell wall and cleaving the pentaglycine cross-bridges present in
Staphylococcus species cell walls [106]. This molecule would be of particular interest to the field
of orthopedics as Staphylococcus species dominate orthopedic biofilms. Bai Xue et al recently
developed a hydroxyapatite/chitosan composite bone cement, incorporated with lysostaphin,
shown to be capable of inhibiting S. aureus growth for up to 9 days when tested in vitro, but the
material had set time greater than 90 minutes, which is not clinically relevant [107]. Smeltzer et
al have also targeted their research for the eradication of S. aureus species within the context of
orthopedics by developing gold nanoconstructs conjugated to different antibodies, loaded with
antibiotics, and using laser irradiation to active a photothermal effect [108]. However, this
technology has its limitations with no in vivo models being done due to the unknown effect of
the photothermal activity on tissues. Allison et al took a different approach to targeting biofilms
with their study outlining how mannitol acts a metabolic stimulant for bacteria, reversing the
persister cell state by promoting a directional shift in metabolic reactions within the cell, thereby
facilitating the uptake of aminoglycosides [25, 49]. This mechanism was tested in vivo within a
mouse urinary catheter model against E. coli biofilm, which highlighted this system’s ability to
eradicate the infection. Although Barraud et al further demonstrated synergism with mannitol
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and tobramycin when tested against Pseudomonas aeruginosa, neither study demonstrated
methods for the delivery of mannitol and antibiotics to infected or contaminated tissue. [25, 26,
49].
Mannitol
With the prevention and treatment of biofilms being of particular interest to the realm of
orthopedics, mannitol, a polyalcohol and a known bacterial metabolite, was sought to act as a
way to shift the metabolic reactions of dorman persister cells within the biofilm, and
subsequently targeting the cells that aid the biofilms survival [24, 25]. Mannitol, in conjuction
with a chitosan local antibiotic delivery system, could serve as a way to ensure the eradication of
persister cells. Mannitol has many unique functions in both the medical and food industries. It is
primarily used as an artificial sweetener, being about half as sweet as sucrose, and is naturally
found in marine algae, fresh mushrooms, and trees [109]. Mannitol is available commercially in
a variety of water-soluble powder and granular form [109]. In the medical industry, it is
primarily used for its osmotic properties for the treatment of renal failure, cerebral edema,
ischemia-reperfusion injury, and cystic fibrosis.[109, 110]
To further elaborate on the study done by Allison et al, they were able to demonstrate that
persister cells are primed for metabolite uptake, central metabolism, and respiration, even though
they are dormant [25]. After a metabolic stimulus is introduced, persister cells begin to awaken
by the activation of a proton-motor force, which shifts the metabolic reactions in to a state
promoting the uptake of antibiotics. Aminoglycosides work on the 30S ribosomal unit, which
remains active even in the persister cell state, and can therefore be used in conjuction with a
metabolic stimulus to eradicate dormant persister cells [25]. Allison et al were additionally able
to prove that this mechanism does not rely on full growth resumption and proved it to be
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effective in both aerobic and anaerobic conditions. Gentamicin in particular was found to be
greatly potentiated by persister cells in the presence of mannitol and the combination induced the
rapid killing of persister cells and reduced the overall bacterial viability of the biofilm (Figure 2)
[25].

Figure 2. Specific metabolites enable aminoglyoside killing of E. coli persisters a. survival of
persisters after 2-hour treatment with gentamicin and respective metabolite, b. metabolite
induced persister elimination superimposd on metabolic network, c. survival of persisters after
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the indicated treatments, d. metabolite induced gent-TR uptake by stationary phase cells super
imposed on metabolic network [25].
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CHAPTER III
INHIBITION AND ERADICATION OF BACTERIAL BIOFILM BY INJECTABLE
MANNITOL-CHITOSAN PASTE
ABSTRACT
Periprosthetic join infections (PJI) are the most common cause of revision surgeries after
total knee arthroplasties and involve significant patient morbidity, as well as an increased
economic burden to the healthcare system. Staphylococcus aureus is the primary pathogen in
PJIs and known to form biofilms not only on implanted materials, but also in the surrounding
tissue. Biofilms are intrinsically less susceptible to antibiotics due to decreased metabolic rates
and the dormant persister cell phenotype. This study sought to evaluate a blend of mannitol,
chitosan and poly(ethylene glycol) as a biocompatible, injectable local antibiotic delivery
system capable of eradicating established biofilm in vitro and preventing osteomyelitis in vivo.
Vancomycin and amikacin were loaded in the paste and elutes were tested for antimicrobial
activity. Cytocompatibility and biocompatibility tests in vivo were performed, as well as in vitro
biofilm studies with and without antibiotics. An osteomyelitis rabbit model with an implanted
titanium pin was used to evaluate the paste’s efficacy at preventing infection. Results indicate
this biomaterial is capable of eluting active antibiotics for up to 7 days, both cytocompatibile
and biocompatible, shows antimicrobial activity against established biofilm with and without
antibiotics, and is capable of preventing infection in vivo. Clinically, this paste could serve as a
biodegradable adjunct therapy for local antibiotic delivery, which could be especially useful in
one-stage revision and retention surgical strategies.
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INTRODUCTION
Periprosthetic joint infections (PJI) throughout the US are increasing as the demand for
joint arthroplasties continues to rise significantly[1]. It is estimated that total knee arthroplasties
(TKA) will exceed 3.45 million procedures per year in 2030 [1,2]. As many as 2% of all
patients who receive TKA risk developing a PJI, with the estimated economic burden on the
healthcare system predicted to exceed $1.60 billion by 2020 [3,4]. These increasing costs are
attributed to revision surgeries, lengthened rehabilitation time, and extended use of antibiotics
and analgesics [5]. Infections cause 25.2% of TKA revisions, making PJI the leading cause for
TKA revisions [6-8]. Two stage revision surgeries are the most common operation for
management of PJIs, being considered the gold standard; however, one-stage revisions and
debridement, antibiotics, and implant retention (DAIR) have significant advantages in patient
outcomes, including improved patient satisfaction, reduced treatment time, and reduced cost for
early onset infections [9,10].
Orthopedic implants can serve as a substrate for biofilm formation, a community of
bacteria, whether pathogens are introduced from surgical contamination or hematogenous
infection [11,12]. Within the biofilm, a subset of bacteria can enter a lower metabolic state,
known as a persister cell, which contributes to an inherent antibiotic resistance allowing the
bacterium to withstand up to 1000x the therapeutic concentration of antibiotics [13]. Recurring
infections are likely if not all microbes are eradicated by tissue debridement, antibiotics, or the
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host immune response [14]. Studies have demonstrated that some bacterial metabolites
stimulate awakening of persister cells, allowing antibiotic to eradicate biofilm [15,16].
Mannitol, a sugar polyol naturally found in marine algae and a common metabolite of bacteria
to generate a proton-motor force within the persister cell resulting in the increased uptake of
internally-acting aminoglycoside antibiotics [15]. The combination of mannitol and gentamicin
was shown to decrease biofilm of S. aureus and E. coli, in vitro and in vivo in a murine urinary
tract infection model [15]. With over 50% of all cases being attributed Staphylococcus species,
these microorganisms are the most prominent pathogen found in PJI [8,17].
The risk of infection becomes even greater during revision surgeries, increasing the need
for an effective method of local antibiotic delivery [18]. Currently, preventative measures
include antibiotic prophylaxis and the use of chlorhexidine-based, povidone-iodine-based, or
alcohol-based solutions to prepare the skin [5,19-21]. During two-stage revision surgeries, local
antibiotic delivery methods utilized include antibiotic-loaded bone cements (ALBC), in the
form of beads and static or articulating joint spacers, as well as the application of topical
antibiotic powder at the time of wound closure [21,22]. However, most ALBC are nonbiodegradable, requiring secondary surgery for removal before the new implant is secured [22].
One-stage revision surgeries, as well as the DAIR technique, could benefit from a
biodegradable antibiotic delivery system that conforms to the complex geometries of the joint
space, to ensure that all pathogens are eradicated even after extensive debridement. There is a
clinical need for not only a local prevention system, but a treatment system as well.
In this study, we sought to evaluate biodegradable and injectable blends of mannitol and
chitosan, an abundant natural polysaccharide derived from the exoskeletons of crustaceans, as
an antimicrobial delivery system. Chitosan has been developed in to a variety of therapeutic
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delivery systems due its characteristics including: biocompatibility, ability to degrade in vivo,
mucoadhesivity, and intrinsic antimicrobial properties [23,24]. Chitosan pastes have the
advantages of being injectable, biodegradable, conformable to surgical defects, and can be
loaded with clinician-selected antibiotics at the time of surgery [25-27]. To evaluate the
hypothesis that mannitol-chitosan blends will elute both antibiotics and mannitol to target
eradication of biofilm-associated S. aureus, elution and efficacy was tested in in vitro and in
vivo preclinical models.
RESULTS
Elution and Antimicrobial Activity
Elution Data
Over the course of the 7-day elution study, each paste group had similar release kinetics,
demonstrating a burst release (Figure 1 a and b). Mannitol eluted in a similar profile, with
minimal but detectable release until day 7 (Figure 2). The ChMPEG-2 paste eluted both
vancomycin and amikacin at detectable levels for 7 days, compared to the Ch-PEG pastes,
which was only able to elute detectable levels of amikacin for 7 days (Figure 1 b).
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Figure 3. Graphical representations show the mean elution concentrations of (a)
vancomycin and (b) amikacin detected for each paste group (n=3). Zoomed in graphs
illustrate the elution data for days 5-7 for both vancomycin and amikacin. Error bars
indicate standard deviation.

22

Figure 4. Graphical representation showing the mean mannitol concentrations eluted
from the ChMPEG-2 and ChMPEG-3 pastes (n=3). Zoomed in graphs illustrate elution
data for days 4-7. Error bars indicate the standard deviation.
Antimicrobial Activity
The results of the Kirby-Bauer study (Table 2) indicate ChMPEG-2 was able to produce
measurable zones until day 7, while the Ch-PEG paste only had measurable zones until day 4.
Any ZOI average measuring below 0.2 mm was reported as 0 mm. Representative pictures of
the zones created by the paste eluate samples are below (Figure 3).
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Table 1. Table indicating the Zone of Inhibition (mm) against S. aureus, measured using
ImageJ software (NIH), for each paste type (n=9). The ± indicates standard deviation.
Paste Group

ChMPEG-2

Ch-PEG

Day 1

5.31 ± 0.19 mm

6.18 ± 0.16 mm

Day 2

4.37 ± 0.31 mm

4.92 ± 0.29 mm

Day 3

2.92 ± 0.19 mm

1.99 ± 0.08 mm

Day 4

2.40 ± 0.20 mm

0.42 ± 0.19 mm

Day 5

1.18 ± 0.17 mm

0 mm

Day 6

0.61 ± 0.32 mm

0 mm

Day 7

0.22 ± 0.04 mm

0 mm

Figure 5. Graphical table illustrates representative images of the ZOI created around the
6 mm paper disc loaded with different paste eluate day samples. ZOI was measured using
ImageJ (NIH).
In vitro Cytocompatibility
All paste types and the control sponge were above the accepted 70% value when
normalized to the blank standard, in accordance with the ISO 109935 Biological Evaluations of
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Medical Devices standard when evaluating biomaterials against fibroblasts and the groups were
not statistically different from one another (Figure 4).

Figure 6. Graphic representation of cytocompatibility results for each paste type when
evaluated with NIH-3T3 fibroblasts cells. Error bars indicate standard deviation and the black bar
line represents the accepted value of 70% according to ISO 109935.
Biocompatibility model with Sprague Dawley Rats
Representative histological sections of each paste group showed that paste groups elicited
mild to moderate inflammation in the rat biocompatibility model (Figure 5). Histological scores
by five blinded raters indicate a greater inflammatory response in the ChMPEG-2 paste group
when compared to the Ch-PEG, but not a statistically different response (Figure 6).
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Figure 7. Graphical table illustrating three representative samples of each paste time after
week 1. Histological imaging of each paste type (n=8) was graded by blinded reviewers (n=5).
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(a)

(b)

Figure 8. Scatter plot shows mean histological scores for each rat (n=8) in biocompatibility
model. (a) illustrates the scores after the week 1 time point and (b) illustrates the scores after the
week 4 time point.
In vitro Biofilm Studies
MBEC™ Peg Plate
Each paste group, except the Ch-PEG paste with no antibiotics, decreased bacterial
viability after 24 hours of incubation after the S. aureus biofilm was submerged in paste (Figure
7 a). For the paste eluate study, all groups except Ch-PEG no antibiotics, showed a decrease in
bacterial viability, (Figure 7 b).
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(a)

(b)

Figure 9. Scatterplot (a) represents bacterial viability of S. aureus after direct contact with
the pastes (n=6) and scatterplot (b) represents bacterial viability after direct contact with day-one
eluates of paste (n=6). Bacterial viability was normalized to a blank standard. The abbreviation
ABX indicates antibiotics.
Staphylococcus Aureus on Rabbit Bone
For this study, both paste groups loaded with antibiotics reduced mean viability of an S.
aureus biofilm, though differences were not significant at the alpha = 0.05 level (p = 0.07) (Figure
8).
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Figure 10. Scatter plot shows the CFU counts for S. aureus (UAMS-1) from rabbit bone
incubated for 24 hours with direct contact of ChMPEG-2 and Ch-PEG pastes, both with and
without antibiotics (ABX).
Animal Model
Osteomyelitis Model in New Zealand White Rabbits
All of the groups included in this study, minus the no treatment group, contained
antibiotics. Both paste groups were capable of preventing the propagation of S. aureus in the
context of the rabbit osteomyelitis model. CFU counts obtained from the titanium pin collected
after three weeks indicated only the Ch-PEG and ChMPEG-2 groups were able to inhibit bacteria
from attaching to the pin consistently (Figure 9). The ChMPEG-2 paste demonstrated an
increased antimicrobial effect in the context of the surrounding tissue culture swab, being the
only group with no breakthroughs to soft tissue (Figure 10 a). For the bone culture swabs, PMMA
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was the only experimental group to show total eradication from bone, but the ChMPEG-2 paste
only had one break through (Figure 10 b). Statistical analysis showed all groups to be statistically
different from the no treatment group.
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Figure 11. Scatter plot shows CFU counts of S. aureus (UAMS-1) collected from the
harvested Titanium pin of each rabbit (n=6) * Indicates a statistically significant difference
between the no treatment group and the treatment groups.
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(a)

(b)

Figure 12. Scatterplot (a) indicates the positive (bacterial growth) and negative (no
bacterial growth) results of the surrounding soft tissue (n=6) and (b) indicates the positive and
negative results of the bone (n=6). Each were swabbed during the retrieval of the Titanium pin
after three weeks for each group. The abbreviation Tx stands for treatment. * Indicates
statistically significant difference between the no treatment group.
DISCUSSION
The mannitol-chitosan blend was able to form a biomaterial capable of being loaded at the
time of care with choice antibiotics. In the context of PJI, this material could serve as a degradable
local antibiotic delivery system during one-stage and DAIR revision surgeries. An added layer of
antimicrobial protection could lead to a decrease in the number of recurring infections after these
different PJI treatment strategies.
The improved elution of antibiotics from mannitol blends may be due to the formation of
a polyelectrolyte complex, with the interaction of mannitol hydroxyl groups and the positively
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charged amine groups present on chitosan. Chitosan forms polyelectrolyte complexes with salts
of polyols [28,29]. The most commonly reported complex is the thermogelling combination of
beta-glycerophosphate and chitosan [26,30,31]. A local delivery system with betaglycerophosphate and chitosan reported by Boles et al. only eluted amikacin and vancomycin
until day 5, with antimicrobial activity against S. aureus for only 3 days [26]. The increased
duration of elution for the mannitol blend could be attributed to differences in the hydration
procedure and amount, leading to stronger intermolecular interactions between chitosan with less
water in in the system [26,27]. In chitosan pastes with PEG only, elution duration was only
reported for 72 hours, as well as the antimicrobial activity [25,27]. The properties of chitosan
biomaterials can also be tailored by the degree of deacetylation, molecular weight, temperature,
and pH. While these parameters were not assessed during this investigation, it may be possible
to tailor the release characteristics and other properties through the control of these factors.
Cytocompatibility studies show similar results to the chitosan injectable pastes described
by Berretta et al and indicate that mannitol’s addition to the system does not affect the cellular
response to the paste [25]. Mannitol is a Food & Drug Administration (FDA) approved food
sweetener, as well as a medication used as an osmotic agent to decrease swelling in the brain, for
the prevention of acute renal failure, and for pulmonary conditions like cystic fibrosis in order to
draw fluid out of the lungs [32,33]. No adverse side effects were expected to be observed upon
the addition of mannitol to the system [34]. Chitosan is also known to be biocompatible and
degrades within the body by lysozyme and acid dissolution. Chitosan first breaks down into long
oligosaccharide chains, with its final end product being glucosamine. This monosaccharide is
known to be biocompatible as well with recent studies showing it may be effective at pain
management for people with osteoarthritis, although it has not be approved for this use by the
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FDA [35]. The acidic dissolution of chitosan, and subsequent inflammation, could be increased
in the form of a hydrated paste, unlike the minimal pathological inflammation results found with
chitosan sponges in vivo [36]. These acidic dissolution products could be responsible for the
reported slight increase in inflammatory response of the paste groups when compared to
previously reported chitosan biomaterials like the beta-gylcerophosphate chitosan paste, which
was attributed to the neutralizing effect of beta-gylcerophosphate [26]. In the context of a biofilm
infection, an active inflammatory response with macrophage and neutrophil presence is required
for the body’s innate immune response to remain active at creating an environment unsuitable for
biofilm growth or the release of planktonic bacteria [37]. Additionally, the inflammatory response
seen with the ChMPEG-2 paste could also be the result of mannitol acting as an osmotic diuretic.
The osmotic effect of mannitol when introduced in to the body is confined to the extracellular
space in which it is introduced and can draw fluid from the intracellular space of the surrounding
cells to maintain osmotic equilibrium [34].
The mannitol component of the mannitol-chitosan paste may combat biofilm formation by
targeting the persister cell phenotype. The ChMPEG-2 paste exhibited antibiofilm properties even
in the absence of antibiotics during several in vitro studies. The release of mannitol may activate
the proton-motor force of persister cells, increasing the activity of aminoglycosides delivered by
the paste [16,38]. Chitosan has known antimicrobial properties and mannitol may also increase
susceptibility to the acetic acid solvent of the paste or the cationic chitosan itself [39]. The actual
mechanism as to why chitosan exhibits antimicrobial activity is not yet fully understood, but may
be attributed to low molecular weight chitosan penetrating bacterial cell walls, binding with DNA
and inhibiting transcription or by forming an impermeable layer around the cell, changing cell
permeability and blocking transport into the bacterial cell [40-42]. Chitosan alone has shown
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antimicrobial activity against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus
epidermidis, and S. aureus[39] Through the combination of mannitol and chitosan, this
biomaterial has demonstrated enhanced antimicrobial activity by reducing bacterial viability of
established biofilms Due to the results of the in vitro bone model of osteomyelitis, only antibiotic
loaded pastes were selected for the in vivo model.
In the in vivo model, the ChMPEG-2 paste proved to be more effective at preventing the
propagation of osteomyelitis, which may be due to improved release of antibiotics, the mannitol
acting as a biofilm disrupter, while awakening persister cells within the biofilm to be more
susceptible to the antibiotics or cationic chitosan. Recent studies have outlined the antibiofilm
properties of erythritol, another sugar alcohol similar in structure to mannitol, suggesting that
erythritol is capable of diffusing in to the biofilm matrix and weakening the hydrogen bonds
between the hydroxyl groups of exopolysaccharides present [43]. Lim et al recently attached
erythritol to the positive end of the zwitterion, betaine, to show a reduction in Streptococcus
mutans biofilm adhesive forces due to an increase in solubility of bacterial exopolysaccharides
[43]. A similar effect could be achieved due to the mannitol-chitosan blend, in which mannitol
release acts in concert with the positively charged amine groups of chitosan to disrupt the
adhesion of biofilm. This would lead to the creation of an environment unfavorable to the
development of a biofilm, preventing an infection before it is allowed to propagate.
In conclusion, the mannitol-chitosan blend exhibited an improved elution profile, enhanced
antimicrobial properties, antibiofilm properties observed with and without antibiotics, and
efficacy at prevention osteomyelitis in vitro. This material could be clinically applied in the
context of one-stage revision surgeries or DAIR surgical strategies after a periprosthetic joint
infection to improve the overall outcome of these treatment options. Future studies will include
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the evaluation of ChMPEG-2 paste’s efficacy at eradicating established osteomyelitis, induced
by S. aureus (UAMS-1) in a rabbit model. Subsequent in vitro tests will measure the antibiofilm
properties of the mannitol-chitosan blend against different species of bacteria, relevant to
periprosthetic joint infections including methicillin resistant S. aureus, Staphylococcus
epidermidis, and Escherichia coli, as well as Pseudomonas aeruginosa. Additionally, in vivo
models to evaluate the paste’s efficacy for the prevention of infection, without adjunct antibiotics,
will need to be evaluated.
MATERIALS AND METHODS
Fabrication
Chitopharm S chitosan powder (Chitinor AS, Tromsø, Norway) with an 82.46 ± 1.679
degree of deacetylation and an average molecular weight of 250.6 kDA was dissolved at 1%
(weight/volume) and 1% (weight/volume) 8,000 g/mol PEG (Sigma Aldrich, St. Louis, MO)
dissolved in 0.85 % acetic acid in deionized water solution. 2% mannitol (mannitol
(Bulksupplements.com) was also dissolved in the previous solution to form the mannitol paste
group. The solutions were cast in 25 mL aluminum dishes and frozen overnight at -80°C, then
lyophilized in a benchtop freeze dryer (LabConco, Kansas City, MO) to create acidic dehydrated
sponges. The sponge types were then ground separately into a fine powder and stored in a
desiccator until use. After preliminary determination of the hydration ratio by evaluating the
consistency of the paste when mixed by two coupled syringes (via Interlok™, Qosina). A 3 mL
syringe filled with 1.25 mL of PBS and connected to a 10 mL syringe with 500 mg of ground
powder, the PBS was injected into the ground powder and the mixture as passed back and forth
between syringes until evenly mixed.
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Elution & Antimicrobial Activity
Antibiotics were passively loaded into the paste by replacing the PBS solution desceibed
previously with a solution of vancomycin and amikacin, both at a 10 mg/mL concentration, in
PBS. Pastes (0.3 mL, n=3) were injected into a 12 well CellCrownTM insert fitted with a 44 µm
nylon filter and submerged in 4 mL of PBS. Sampling occurred daily for 7 days with complete
refreshment. Antibiotic concentrations were evaluated with high performance liquid
chromatography using a ThermoScientific Dionex Ultimate 3000 Series HPLC system and a BDS
Hypersil reversed-phase C18 column (150 x 4.6 mm). Vancomycin was detected with a UV/Vis
spectrophotometer and amikacin was quantified using pre-column derivatization with an ophthaldialdehyde reagent and subsequent detection using a fluorescence detector.
Activity of antibiotics in eluate samples (n=3) was assessed using a zone of inhibition
(ZOI) assay. On trypticase soy agar plates with S. aureus (UAMS-1) lawns grown overnight and
diluted 1:10 in TSB. Eluate samples (30µL) were loaded on to blank paper discs (6 mm =
diameter) and placed on the bacterial lawns and allowed to incubate at 37°C for 24 hours. The
plates were then photographed and ZOI diameters were measured using ImageJ (NIH).
Cytocompatibility
NIH 3T3 fibroblasts were seeded at 104 cells/cm2 in a 24 well plate and grown in
Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum and 100
µg/mL of Normocin antibiotic/antimitotic solution for 24 hours at 37 °C and 5% CO2.The
different paste types (n=3) were compared to a neutral chitosan sponge and blank wells. Samples
were sterilized with ethylene oxide gas (EtO) prior to testing. The pastes were hydrated with PBS
and a volume of 0.2 mL was inserted into cell culture inserts (Falcon, pore size = 8 µm). Cell
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viability was quantified using Cell-Titer Glo (Promega) after 24 hours of exposure to the pastes.
Results were normalized to the blank standard.
Biocompatibility model with Sprague Dawley Rats
This animal model was approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Memphis (#0811). 16 Male Sprague Dawley Rats (~375 g) were
divided into 2 groups; ChMPEG-2 paste, Ch-PEG paste, at two time points (1 week and 4 weeks)
(n=8/group/time point). Rats were anesthetized using isoflurane inhalation with their backs
shaved and cleaned with betadine and isopropanol. Each rat received both implant groups,
inserted at separate and randomized locations on its back with the midline separating the groups.
0.3 mL of pastes hydrated with PBS were placed subcutaneously after an approximately 1 cm
long incision was made, and surgical scissors were used to create the subcutaneous pouch.
Following the two time points, rats were sacrificed and the skin tissue surrounding the remaining
material was harvested for histological analysis with H&E staining. Reviewers blinded to group
identification (n=5) rated inflammation on a scale of zero to five with zero indicating no
inflammation and five indicating severe inflammation. Inflammation was assessed grading the
severity of the fibrous capsule and the reaction zone surrounding the implant, with more purple
correlating to an increase in the presence of the host’s immune cells.
In-vitro Biofilm Studies
MBEC Plate Studies
Pastes, including Ch-PEG, ChMPEG-2, and ChMPEG-3, were hydrated with a 5 mg/mL
amikacin and vancomycin and evaluated against established biofilms of S. aureus (UAMS-1)
grown overnight in MBEC™ 96 well plates with 150 µL at concentrations of 106 CFU in TSB.
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After 48 hours, pegs of the MBEC™ plates were fitted into a new 96 well plate after 0.15 mL
(n=6) of each paste type was injected in to the well. Additionally, eluate activity was evaluated
by submerging the pegs in 150 µL (n=6) of the first day eluate sample taken from the elution
study. Controls of 0, 0.05, 0.5, and 5 mg/ml of vancomycin and amikacin in PBS were also
included as negative and positive controls. After 24 hours, the tops of the MBEC™ plates were
removed, placed in fresh TSB, sonicated for 5 minutes, and incubated for 24 hours. Presto Blue™
viability reagent was used to compare bacterial survival on pegs and growth after exposure to
paste or eluates. Percent viability was determined using the to the blank standard (0 mg/ml
antibiotic).
Staphylococcus Aureus on Rabbit Bone
Bone was harvested from the femur, tibia, and humerus of male New Zealand white rabbits
under aseptic conditions and cut into small 0.5 cm long cylinders, as an adaptation of the in vivo
model described by Badha et al [44]. Bone samples were placed into 12 well plates with 500 µL
of PBS and inoculated with 100 µL of 105 colony forming unit (CFU) concentration of S. aureus
(UAMS-1). Pastes, including Ch-PEG and ChMPEG-2 (0.3 mL, n=3), were injected into the
medullary canal and on top of the bone sample, then incubated overnight at 37°C. A crosssectional schematic diagram of this in vitro model can be seen in Figure #. The paste was removed
and the bone placed in 2.50 mL of PBS to be sonicated for 5 minutes. The resulting solution was
used to quantify bacterial presence by CFU counts.
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Figure 13. Illustration of the in vitro osteomyelitis prevention model using harvested rabbit
bone tissue and S. aureus (UAMS-1) as the pathogen.
Osteomyelitis Model in New Zealand White Rabbits
This animal model was approved by the IACUC at the University of Arkansas Medical
Sciences (#3608) with all appropriate measures were taken to minimize pain and discomfort. This
in vivo model is an adaptation of the work by Smeltzer et al [45]. Female New Zealand White
rabbits weighing 2-3 kg were divided into 5 groups (n=6/group) including the following: no
treatment control, a hollow PMMA (Orthoset, MicroPort Memphis, TN) cylinder with amikacin
and vancomycin (approximately 15 mg/implant), a vancomycin sprinkle of 10 mg, the chitosanPEG paste (Ch-PEG), and the chitosan-mannitol-PEG paste (ChMPEG-2). Rabbits were
anesthetized with 1-2 cc of a xylazine/ketamine mixture intramuscularly for a dose range of 3-7
mg/kb xylazine and 30-40 mg/kg ketamine. Rabbits were maintained on isoflurane administered
by nose cone to produce surgical anesthesia and monitored by a veterinary technician. The right
forelimb of each rabbit was shaved and prepped using a betadine scrub and rinsed with 70%
ethanol. An incision was made on the anterior surface of the right forelimb through the epidermis,
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musculature, and fascia until the radius was exposed. A 1 cm mid-radial segment was be excised
from the right radial bone using a miniature saw blade (Exakt, Oklahoma City, OK). The excised
segment was then infected by inoculation of S. aureus [10 μL of 106 colony forming units
(CFUs)/mL; UAMS-1 strain] directly into the intramedullary canal on both the proximal and
distal ends of the radius. A titanium pin (0.9 mm diameter, 2 cm length) was placed back into the
defect via the medullary canal. However, for the PMMA group, the bone segment was left out
and the titanium pin inserted into the hollow PMMA cylinder to be placed back into the defect.
Rabbits were euthanized after 3 weeks with swabs of bone and surrounding soft tissue taken for
analysis of present microorganisms, and the pin retrieved and sonicated in PBS for bacteriological
analysis.
Statistical analysis
Statistical analysis was performed using SigmaPlot and GraphPad Prism 7.2 software
(GraphPad Software Incorporation, La Jolla, CA, USA). The elution data was assessed with a
two-way analysis of variance (ANOVA) followed by Holm-Sidak’s post-hoc analysis to detect
significant differences with time and experimental group. Cytocompatibility results were
assessed with a one-way ANOVA followed by Holm-Sidak’s post-hoc analysis used to detect
statistical differences among experimental groups. In vivo functional compatibility results and the
CFU counts of various bacterial studies are non-parametric and therefore analyzed using a
Kruskal-Wallis one-way ANOVA. Proportion of infected versus cleared culture swabs were
assessed using the Fisher Exact test (α = 0.05)
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CHAPTER IV
DISCUSSION
PJI is a devastating outcome after a total joint arthroplasty associated with severe patient
morbidity and an increased economic burden to the healthcare system [16, 113]. One-stage
revision surgeries and the DAIR surgical technique offer advantages to decrease the overall
recovery time, and provide similar patient outcomes to the gold standard, the two-stage revision
surgery [35, 36]. The DAIR method is reserved for patients who could serve to maintain the
implant, decreasing costs and rehabilitation times even further [35]. However, these techniques
range in efficacy with as low as 13% to 100%, due to the insufficient debridement of bacteria,
poor systemic delivery of antibiotics, and the lack of a local antibiotic delivery system during the
revision, unlike the two-stage approach, to eradicate any pathogens that may be indwelling
within a biofilm [35-38]. Mannitol was hypothesized to increase the efficacy of aminoglycoside
antibiotics by activating the proton motor force by acting as a bacterial metabolite [25]. A
preliminary study quantifying the adenosine triphosphate (ATP) production of established
biofilms after exposure to mannitol when compared to a standard media showed an increase in
activity for both P. aeruginosa and S. aureus (Appendix A). Moving forward, mannitol was
added in concentrations from 2% to 18% to a chitosan-poly(ethylene glycol) blend to establish if
it would form a gel-like complex. After evaluation, the 2% and 3% mannitol blends were used to
test the mannitol-chitosan blend’s efficacy at the prevention and treatment of a biofilm.
(Appendix B). These mannitol chitosan blends, able to form an injectable biodegradable
biomaterial loaded with choice antibiotics, could serve as a local delivery system for both onestage and DAIR revisions (Appendix C). This study showed an increased efficacy for biofilm
eradication in several in vitro models with the mannitol paste, as well as the ability to prevent an
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osteomyelitis infection in vivo. This added layer of antimicrobial protection could lead to a
decrease in the number of recurring infections after these PJI treatment strategies.
The improved elution of antibiotics from mannitol blends may be due to the formation of
a polyelectrolyte complex, with the interaction of mannitol hydroxyl groups and the positively
charged amine groups present on chitosan. Chitosan forms polyelectrolyte complexes with salts
and polyols [115, 116]. The most commonly reported complex is the thermogelling combination
of beta-glycerophosphate and chitosan [48, 117, 118]. A local delivery system with betaglycerophosphate and chitosan reported by Boles et al. only eluted amikacin and vancomycin
until day 5, with antimicrobial activity against S. aureus for only 3 days [48]. The increased
duration of elution for the mannitol blend could be attributed to differences in the hydration
procedure and amount, leading to stronger intermolecular interactions between chitosan with less
water in in the system [47, 48]. The properties of chitosan biomaterials can also be tailored by
the degree of deacetylation, molecular weight, temperature, and pH. While these parameters
were not assessed during this investigation, it may be possible to tailor the release characteristics
and other properties through the control of these factors.
Cytocompatibility studies show similar results to the chitosan injectable pastes, described
by Berretta et al, and indicate that mannitol’s addition to the system does not affect the cellular
response to the paste [46]. Mannitol is a Food & Drug Administration (FDA) approved food
sweetener, as well as a medication used as an osmotic agent to decrease swelling in the brain, for
the prevention of acute renal failure, and for pulmonary conditions like cystic fibrosis in order to
draw fluid out of the lungs [109, 110]. No adverse side effects were expected to be observed
upon the addition of mannitol to the system [110]. Chitosan is also known to be biocompatible
and degrades within the body by lysozyme and acid dissolution. Chitosan first breaks down into
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long oligosaccharide chains, with its final end product being glucosamine. This monosaccharide
is known to be biocompatible as well with recent studies showing it may be effective at pain
management for people with osteoarthritis, although it has not be approved for this use by the
FDA [120]. The acidic dissolution of chitosan, and subsequent inflammation, could be increased
in the form of a hydrated paste, unlike the minimal pathological inflammation results found with
chitosan sponges in vivo [121]. This would cause a greater inflammatory response than
previously reported with chitosan biomaterials like the beta-gylcerophosphate chitosan paste,
which was attributed to the neutralizing effect of beta-gylcerophosphate [48]. Additionally, the
inflammatory response seen with the ChMPEG-2 paste could be the result of mannitol acting as
an osmotic diuretic. The osmotic effect of mannitol when introduced in to the body is confined to
the extracellular space in which it is introduced and can draw fluid from the intracellular space of
the surrounding cells to maintain osmotic equilibrium [110]. In the context of a biofilm infection,
an active host inflammatory response with macrophage and neutrophil presence is required for
the body to continue to create an environment unsuitable for biofilm growth or the release of
planktonic bacteria from the biofilm. Degradation results of the paste indicated an extended
degradation, but studies have shown that in vitro models of degradation for chitosan biomaterials
may not be the best way to assess degradation [127]. The in vivo biocompatibility model showed
a decrease in paste volume by week 1 from some samples and a decrease in paste volume for
other samples. Degradation could be improved by altering the DDA or increasing the hydration
ratio. Decreased DDA would decrease the strength of the polyelectrolyte complex due to the
bulky side-chain acetyl groups, but this in turn might also decrease the elution time.
The mannitol component of the mannitol-chitosan paste may combat biofilm formation
by targeting the persister cell phenotype. The ChMPEG-2 and ChMPEG-3 pastes exhibited
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antibiofilm properties even in the absence of antibiotics during several in vitro studies with
Staphylococcus aureus (UAMS-1)The release of mannitol may activate the proton-motor force
of persister cells, increasing the activity of aminoglycosides delivered by the paste [25, 26].
Chitosan has known antimicrobial properties and mannitol may also increase susceptibility to the
acetic acid solvent of the paste or the cationic chitosan itself. The actual mechanism as to why
chitosan exhibits antimicrobial activity is not yet fully understood, but may be attributed to low
molecular weight chitosan penetrating bacterial cell walls, binding with DNA and inhibiting
transcription or by forming an impermeable layer around the cell, changing cell permeability and
blocking transport into the bacterial cell [99, 122, 123]. Chitosan alone has shown antimicrobial
activity against Escherichia coli, Staphylococcus epidermidis, and S. aureus [98]. Combining
these to mannitol has demonstrated enhanced antimicrobial activity by providing a material
capable of reducing bacterial viability within a biofilm. Due to the results of the in vitro bone
model of osteomyelitis, only antibiotic loaded pastes were selected for the in vivo model.
In the in vivo model, the ChMPEG-2 paste proved to be more effective at preventing the
propagation of osteomyelitis, which may be due to improved release of antibiotics, the mannitol
acting as a biofilm disrupter, while awakening persister cells within the biofilm to be more
susceptible to the antibiotics or cationic chitosan. Recent studies have outlined the antibiofilm
properties of erythritol, another sugar alcohol similar in structure to mannitol, suggesting that
erythritol is capable of diffusing in to the biofilm matrix and weakening the hydrogen bonds
between the hydroxyl groups of exopolysaccharides present [124]. Lim et al recently attached
erythritol to the positive end of the zwitterion, betaine, to show a reduction in Streptococcus
mutans biofilm adhesive forces due to an increase in solubility of bacterial exopolysaccharides
[124]. The same effect could be achieved due to the mannitol-chitosan blend, in which mannitol
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release acts in concert with the positively charged amine groups of chitosan to disrupt the
adhesion of biofilm. This would lead to the creation of an environment unfavorable to the
development of a biofilm, preventing an infection before it is allowed to propagate.
CHAPTER V
CONCLUSIONS
The mannitol-chitosan blend has proven to be an effective way to prevent the propagation
of the bacterial pathogen, S. aureus, both in vitro and in vivo. This material could be clinically
applied in the context of one-stage revision surgeries or DAIR (debridement, antibiotics and
implant retention) surgical strategies after a periprosthetic joint infection or in complex
orthopedic trauma cases. The mannitol-chitosan blend exhibited an improved elution profile
when compared to the previously researched chitosan-PEG paste, while also exhibiting extended
antimicrobial activity. Additionally, the mannitol-chitosan blend was tested in vitro against both
S. aureus and P. aeruginosa biofilms showing an increased efficacy at eradication when
compared to the Ch-PEG paste, with and without antibiotics. The 3% paste group was excluded
from the in vivo models based on the elution and antimicrobial data showing the 2% paste was
more effective at prevention bacterial growth. The ChMPEG-2 paste exhibited cytocompatibility
properties when tested against NIH-3T3 cells and a moderate inflammatory response when tested
in vivo. The ChMPEG-2 proved to be effective in vivo at preventing an osteomyelitis infection in
the context of a rabbit model with an implanted Titanium pin and surrounding tissue. All of these
factors conclude that this material could be used in the context of PJI revision surgery
techniques, even branching off to other surgical procedures with devastating effects after
infection, in order to decrease the rate of recurring infection. This material can be loaded at the
time of care with physician chosen antibiotics, degrade within the body, and target any remaining
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biofilm or bacteria within the joint space or attached to an implant or tissue by being injected
into the site before wound closure.
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CHAPTER VI
FUTURE WORK
Several studies are planned to continue the evaluation of this novel mannitol-chitosan
blend, including the evaluation of the paste’s efficacy at eradicating established osteomyelitis,
induced by S. aureus (UAMS-1) in a rabbit model. For further in vivo characterization, the paste
will be evaluated against infection without antibiotics, which would help to understand which
regulatory pathway to take in order to seek FDA approval, commercialize, and move the
mannitol-chitosan paste in to human clinical trials. Subsequent in vitro tests will measure the
antibiofilm properties of the mannitol-chitosan blend against different species of bacteria,
relevant to periprosthetic joint infections including methicillin resistant S. aureus,
Staphylococcus epidermidis, and Escherichia coli. Additionally, studies will be designed to
evaluate the inflammatory response by testing the mannitol-chitosan paste against monocytes to
monitor their differentiation into macrophages, as well as testing the paste against bone cells to
give a better picture of how the paste will behave within a joint space. In order to improve the
degradation characteristics to better match the elution properties, the DDA as well as the
hydration ratio could be tailored for further gel characterization. To further study the interaction
polyols have with chitosan, erythritol will be evaluated as the polyol addition to offer another
avenue for the eradication of biofilm based on a metabolite response. Finally, the elution profiles
of different antibiotics from the mannitol-chitosan paste will be evaluated to offer a clear picture
to physicians looking to utilize this new technology within their field. Further areas of
application for the paste will also need to be evaluated including traumatic musculoskeletal
wounds, biofilm present on soft tissue, surgical site infections, and dental procedures.
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APPENDIX A
Preliminary Data on Mannitol’s Effect on Biofilm
Rationale & Methods
In the original article by Allison et al, mannitol was shown to have a synergistic effect on
biofilm with aminoglycosides. This effect was reasoned to occur due to mannitol acting as an
energy source for the bacteria, while activating a proton motor force. This in turn would lead to
the increased uptake of aminoglycosides. In order to test this, ATP production by the biofilm
would need to be increased, because if the proton motor force is in fact being activated, it would
lead to an upward spike in ATP production. This was tested using a simple biofilm model using
Staphylococcus aureus (UAMS-1) and Pseudomonas aeruginosa (PAO1) was implemented.
Bacterial cultures of S. aureus and P. aeruginosa were incubated overnight in TSB and LB Broth
(Gibco, LifeTechnologies), 105 CFU and 150 L of each strain was seed on to a 96 well plate.
These plates were incubated for 48 hours with no media change. The media was then siphoned
off and replaced with mannitol solutions of varying concentrations (10 mM, 40 mM, and 80
mM) in M9 medial salts (Gibco, LifeTechnologies). These concentrations were chosen based off
the finding by Allison et al that the optimal concentration is around ~40 mM. M9 minimal salts
were chosen to ensure the bacteria were nutrient starved and forced to use mannitol as a source
of energy. The plates were then incubated for an additional 24 hours and after, all media
solutions were siphoned off and the wells were washed with M9 minimal salts three times to
remove any planktonic bacteria. Bacterial viability was assessed using Bac-Titer Glo Reagent
Luminescence was assessed using BioTek plate reader and results were statistically analyzed
using SigmaPlot.
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Results
With the addition of varying mannitol concentrations in M9 minimal salts, an increase in
ATP production was found after using Bac-Titer Glo Viability reagent was used. The increase in
ATP production was especially prevalent when compared to the M9 minimal salts alone. In the
case of S. aureus, an increase in mannitol concentration did not lead to an increase in ATP
production, but rather a decrease. For P. aeruginosa, the increase in mannitol led to a nonsignificant increase in ATP production. These results are illustrated in the figures 14 and 15
below.

Figure 14. ATP production from S. aureus after incubation in M9 minimal salts, TSB, or
varying concentrations of mannitol in M9 minimal salts (n=3).
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Figure 15. ATP production from P. aeruginosa after incubation in M9 minimal salts, LB
Broth, or varying concentrations of mannitol in M9 minimal salts (n=3).
Conclusion
From this study, a dose response connection between bacteria, mannitol, and ATP
production was established after bacteria were immersed in differing mannitol concentrations.
M9 minimal salts forced the bacteria to feed off of mannitol alone. These concentrations were
compared to M9 salts alone, TSB for S. aureus and LB Broth for P. aeruginosa and showed that
there was an increase in ATP production in the presence of mannitol. This led to the idea that
mannitol could be incorporated into an injectable chitosan paste [46]. If mannitol elution could
be achieved along with antibiotic elution from this paste composite, it could offer a method to
prevent biofilm formation but also potentially eradicate existing biofilm in the context of
musculoskeletal trauma, or other types of orthopedic trauma like total joint arthroplasties.
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APPENDIX B
Early Fabrication of Mannitol/Chitosan Paste Composites
Rationale & Methods
After it was determined that mannitol had an increased effect on the ATP production of
bacteria, concentrations ranging from 1% to 18% mannitol were added to an existing
chitosan/PEG paste composite to determine if the material would hold together in PBS. First, the
solubility of mannitol within a 0.85% acetic acid (AcH) solution, the solution used to dissolve
chitosan and PEG for the original paste composite, was determined to be up to 1 Molar of
mannitol. For the original paste, 1% Chitosan and 1% PEG are used, and 1 Molar of mannitol is
the equivalent of around 18% (w/v). Sponges were made with the concentrations of mannitol
listed in Table #. To test if the different composites would remain in a gel-like complex as
previous paste had exhibited, sponges were created [46-48]. The solutions of the different
mannitol, chitosan, PEG solutions (25 mL) were placed into aluminum dishes, frozen at -80 °C,
and lyophilized. These sponges were placed into PBS an incubated in in 37°C to observe
dissolution. These results are also included in Table #. After the working percentages of mannitol
were discovered, the subsequent sponges were ground down and hydrated with PBS at differing
ratios. These ratios were determined to be the lowest amount of PBS needed to hydrate the
ground paste composite. These differing hydration ratios are listed in Table #. This hydrated
construct resulted in the injectable paste. This material was then placed in to PBS, left to sit
overnight in 37°C, and checked the next day to see if the paste remained. The pastes that were
left intact were used in further characterization studies and the results are listed in Table #.
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Results
The higher percentages of mannitol/chitosan composites were not able to hold their shape
when submerged in PBS. 18% concentration dissolved almost instantly when submerged, while
the smaller percentages took a little longer to dissolve. For comparison, a chitosan/PEG sponge
alone will not dissolve in PBS.
Table 2. Each different mannitol concentration added to the chitosan-PEG paste is listed
below, as well as whether or not their sponge constructs dissolved in PBS overnight.
Sponge Intact

Paste Intact

Mannitol (w/v%)

Hydration Ratio
(PBS)

(PBS)

18% no

-

-

10% no

-

-

5% no

-

-

4% no

-

-

3% yes

2.5 mL/g

yes

2% yes

2.5 mL/g

yes

0% yes

4.5 mL/g

yes

Conclusions
After many different mannitol/chitosan compositions were tested with differing mannitol
w/v% concentrations, the 3% and 2% pastes were used for the further characterization of the
mannitol/chitosan paste. These were subsequently named ChMPEG-2 and ChMPEG-3 pastes,
with the control paste (0% mannitol) was named the Ch-PEG paste. The qualitative results of this
study were that the mannitol/chitosan pastes formed a gel-like complex with a lower hydration
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ratio than the previous paste, while the chitosan w/v% did not change. This is believed to be due
to the interaction of the hydroxyl groups present on the mannitol with the positively charged
amine groups present on the chitosan. This characteristic will be further quantified when
explored with various injection studies and adhesion studies. It is believed that this composition
has the potential to increase elution properties of the paste, and the addition of mannitol has the
potential to be more effective at preventing and eradicating biofilm formation.
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APPENDIX C
Injectability Studies
Rationale & Methods
As mentioned previously, it was observed that the mannitol/chitosan paste composites
indicated that there were some favorable intermolecular interactions between the mannitol and
chitosan. This is believed to be due to the hydroxyl groups present on the mannitol and their
interaction with the positively charged amine groups present on chitosan. As the studies
progressed, the paste mixing method was established to be consistent. Ground dry paste was
loaded into a 10 mL syringe (0.5 g for the ChMPEG-2 and ChMPEG-3 and 0.25 g for the ChPEG pastes) which was subsequently connected via an Interlock™ connector (Qosina) to a 3 mL
syringe filled with PBS at the appropriate hydration ratio. This system is pushed back and forth
until the desired consistency was reached. This process is illustrated below in Figure 16.

Figure 16. Paste mixing method involving two syringes, one with dry powder, and the
other with PBS and choice-antibiotics. The two are subsequently mixed back and forth through
an Interlock © coupler.
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Injectability
In order to observe a difference between the mannitol/chitosan and chitosan pastes, an
injectability test was performed through a 1 mL syringe and through an 18 G needle (BD
Products). The force required to eject the paste from both the 1.0 mL syringe (n=3) and the 18G
needle (n=4) was assessed using an Instron Universal Testing Machine with a 5 kN load cell
force plate for each paste composite. The 1 mL syringe was loaded with 1.0 mL of paste and the
syringe with the 18G needle was loaded with approximately 0.5 mL of paste. The ejection force
was automated by Instron’s Bluehill 2 Software, while compressing the syringe plunger at 1
mm/sec for a specified length, 50 mm for 1 mL syringe and 25 mm for the syringe with 18G
needle. The maximum force detected was used for comparison between paste groups. SigmaPlot
was used to statistically analyze the data to determine if they pastes were significantly different.
Results
During the injectability test performed with the 1 mL syringe (no needle), no significant
difference was detected between the different paste groups. For the injectability test with the 18G
needle, the ChMPEG-3 paste was left out due to various results from the elution study and
biofilm studies indicating that the ChMPEG-2 paste was outperforming the ChMPEG-3 paste.
There was a statistical difference detected between the ChMPEG-2 paste and the Ch-PEG paste
during the 18G needle test. These results are illustrated below in Table 3.
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Table 3. This table illustrates the average force needed to eject each paste group from
either a 1 mL syringe (n=3) or a 1 mL syringe with an 18 G needle (n=4). The ** means the two
groups are statistically different.
Paste Group

1mL syringe

18G needle + 1mL syringe

ChMPEG-2 1.20 N ± 0.20 N

18.85 N ± 0.70 N **

ChMPEG-3 1.38 N ± 0.32 N

-

Ch-PEG (control) 1.82 N ± 0.38 N

3.92 N ± 1.64 N **

Conclusion
The characteristics of the mannitol/chitosan paste led to mechanical testing to
quantitatively observe the physical differences of the mannitol-chitosan paste. It was observed
that the mannitol/chitosan pastes were able to create a gel-like complex, more so than the
original chitosan paste. The first injectability test showed the two materials, ChMPEG-2 and ChPEG pastes to be very similar. After the injectability test with the 18G needle, the difference
between these two paste groups became clearer. Both pastes were able to be injected out of both
syringe set-ups, with the ChMPEG-2 paste requiring more force to be extruded. During the 18G
needle test, ChMPEG-2 and Ch-PEG pastes were found to be statistically different. The
qualitative results from this experiment showed the ChMPEG-2 paste to be more adhesive,
sticking to itself, and possibly exhibiting shear-thinning.
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APPENDIX D
Enzymatic Degradation Studies of Different Paste Groups
Rationale & Methods
Enzymatic degradation studies offer an insight in to how a biomaterial will biodegrade.
Chitosan is assumed to be degraded by lysozymes, along with three identified human chitinases,
within the body. [Kean, 10, 11] Knowledge of the elution and degradation characteristics allows
for a better understanding and tailoring of the overall properties of a material. For this study,
each paste type was hydrated in PBS and approximately 0.3 mL (n=3) of hydrated paste was
placed in a 5 mL working volume petri dish (Nucleon). The degradation solution was prepared
by dissolving 1 mg/mL lysozyme type VI (MP Biomedicals) and 100 µg/mL Normocin
antibiotic/antimycotic (MANUFACTURER) in PBS. 5 mL of degradation solution was added to
the petri dish and samples were placed in a 37 °C incubator. Degradation solution was refreshed
every other day by aspirating the media and adding 5 mL of fresh solution. Samples were
collected at the following time points: 1, 3, 5, 7, and 14 days. Degradation solution was siphoned
off and the samples were placed in an oven at 45 °C. After drying, the samples were weighed and
compared to their initial weight to determine the degradation rate. Different samples were used
for each time point.
Results
The chitosan-mannitol pastes continued to degrade over the 14 day period, only reaching
around 30% degraded, while the chitosan paste without mannitol reached a plateau after the first
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day and remaining stagnant in degradation through day 14, degrading about 50%. A graphical
representation of the data is shown in Figure 17.

Enzymatic Degradation Results
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Figure 17. Graphical representation of enzymatic degradation results for various paste with a
1mg/mL lysozyme solution over a 14 day period. (n=3) for each paste at each distinctive time
point. Error bars indicate standard deviation.
Conclusion
The chitosan-mannitol paste showed a longer degradation period when compared to the
chitosan paste without mannitol. The chitosan-mannitol pastes only degraded about 30% while
the chitosan paste group degraded around 50%. This data would further support the conclusion
that a polyelectrolyte complex is forming between the chitosan and the mannitol. A limitation of
this study is that the chitosan-mannitol pastes were hydrated at a lower concentration of PBS (2.5
mL/g) versus the chitosan paste (4.5 mL/g) and this could also attribute to the slower degradation
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rate observed with the chitosan mannitol pastes. For future studies, the hydration ratio of the
different chitosan-mannitol pastes could be evaluated in order to match the degradation
properties of the paste with its elution properties.
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